BI-4020
BI-4020 is a fourth-generation, orally active, and non-covalent EGFR tyrosine kinase inhibitor. BI-4020 inhibits not only the triple mutant EGFR del19 T790M C797S variant (IC50=0.2 nM in BaF3 cell lines) but also the double mutant EGFR del19 T790M and primary mutant EGFR del19 (IC50=1 nM) . BI-4020 also shows activity against EGFR wt (IC50=190 nM) . BI-4020 shows high kinome selectivity and good DMPK properties[1].
Product Specifications
CAS Number
2664214-60-0
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bi-4020.html
Purity
99.30
Solubility
1M HCl : 100 mg/mL (ultrasonic; adjust pH to 1 with HCl) |DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(C1=CC(C)=NC(C2=C(OCCC[C@@H](C)C3)N(C)N=C2)=C1)/N=C(N4)/N3C5=C4C=CC(CN6CCN(C)CC6)=C5
Molecular Formula
C30H38N8O2
Molecular Weight
542.68
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
EGFR/ErbB1/HER1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker) (VU-11D1), CF488A conjugate, 0.1mg/mL
Thyroglobulin (TGB04 + TGB05), CF568 conjugate, 0.1mg/mL
